Urinary peptidome and diabetic retinopathy in the DIRECT-protect 1 and 2 trials
Diabetic Medicine — Curovic VR, Magalhães P, He T, et al. | July 27, 2021
This study attempted to explore the urinary peptidome to presence and deterioration of diabetic retinopathy (DR) in a post hoc analysis of trials investigating the effect of candesartan on progression of DR in type 1 and type 2 diabetes, respectively. Researchers conducted baseline urinary peptidomic analysis on a random selection of 783 and 792 subjects in two randomized controlled trials, DIRECT-Protect 1 and 2, respectively. They compared peptide levels to baseline EDTRS levels in a discovery set of 2/3 of the participants from DIRECT-Protect 1. Several urinary peptides (mainly collagen) associated with the presence of DR were distinguished, nevertheless, they could not be conclusively correlated with worsening of DR.
Read the full article on Diabetic Medicine